Inspire Medical Systems (NYSE:INSP) Rating Lowered to Neutral at Robert W. Baird

Inspire Medical Systems (NYSE:INSP) was downgraded by investment analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report issued on Thursday, MarketBeat Ratings reports. They currently have a $74.00 price objective on the stock, down from their prior price objective of $130.00. Robert W. Baird’s target price would suggest a potential upside of 23.78% from the company’s current price.

Several other research analysts have also commented on INSP. Mizuho reduced their price target on Inspire Medical Systems from $130.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday. Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, October 27th. UBS Group set a $96.00 price target on shares of Inspire Medical Systems in a report on Thursday, January 22nd. Truist Financial cut their price objective on shares of Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday. Finally, Piper Sandler reduced their price objective on shares of Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating for the company in a research note on Thursday. Five analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus target price of $108.94.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $59.78 on Thursday. Inspire Medical Systems has a 1 year low of $53.11 and a 1 year high of $197.75. The firm’s 50-day moving average is $92.88 and its two-hundred day moving average is $90.99. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 6.34 and a beta of 0.74.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, beating the consensus estimate of $0.69 by $0.96. The business had revenue of $269.08 million during the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The company’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 EPS. On average, equities analysts expect that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Insider Activity at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 2,000 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada lifted its stake in shares of Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after buying an additional 4,528 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Inspire Medical Systems during the 1st quarter worth about $524,000. Goldman Sachs Group Inc. grew its stake in Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after purchasing an additional 18,857 shares during the last quarter. KLP Kapitalforvaltning AS increased its holdings in shares of Inspire Medical Systems by 10.5% in the second quarter. KLP Kapitalforvaltning AS now owns 6,300 shares of the company’s stock valued at $818,000 after purchasing an additional 600 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Inspire Medical Systems by 29.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 2,360 shares of the company’s stock worth $306,000 after purchasing an additional 538 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.